These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3872057)

  • 81. Determination of bepridil in biological fluids by high-performance liquid chromatography.
    Ng KT; Plutte JA; Galante LJ
    J Chromatogr; 1984 Jul; 309(1):125-31. PubMed ID: 6332822
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Stability-indicating high-performance liquid chromatography assay for bepridil hydrochloride drug substance and drug products.
    Renzi NL; Fronheiser ME; Duong HT; Fulton DJ; Rabinowitz M
    J Chromatogr; 1989 Jan; 462():398-405. PubMed ID: 2786887
    [No Abstract]   [Full Text] [Related]  

  • 83. Clinical pharmacokinetics of chlorpheniramine.
    Rumore MM
    Drug Intell Clin Pharm; 1984 Sep; 18(9):701-7. PubMed ID: 6383755
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical pharmacology of calcium antagonists.
    Follath F; Taeschner W
    J Cardiovasc Pharmacol; 1988; 12 Suppl 6():S98-100. PubMed ID: 2468919
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effect of polypharmacy on plasma bepridil concentration in patients with heart failure: a multicenter retrospective study.
    Asai Y; Arihara H; Omote S; Tanio E; Yamashita S; Higuchi T; Hashimoto E; Yamada M; Tsuji H; Kondo Y; Hayashi M; Yamamoto Y
    J Pharm Health Care Sci; 2023 Mar; 9(1):10. PubMed ID: 36872399
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity.
    Kang L; Zheng MQ; Morishima M; Wang Y; Kaku T; Ono K
    Br J Pharmacol; 2009 Jun; 157(3):404-14. PubMed ID: 19371335
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.
    Sahin S; Benet LZ
    Pharm Res; 2008 Dec; 25(12):2869-77. PubMed ID: 19015955
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil.
    Schuurhuis GJ; Broxterman HJ; van der Hoeven JJ; Pinedo HM; Lankelma J
    Cancer Chemother Pharmacol; 1987; 20(4):285-90. PubMed ID: 3500807
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Interaction between Ca2+ antagonists and digitalis.
    Lessem JN
    Cardiovasc Drugs Ther; 1988 Jan; 1(5):441-6. PubMed ID: 3154676
    [No Abstract]   [Full Text] [Related]  

  • 90. Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres.
    Berger F; Borchard U; Hafner D
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jun; 339(6):638-46. PubMed ID: 2475788
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.
    Pearigen PD; Benowitz NL
    Drug Saf; 1991; 6(6):408-30. PubMed ID: 1793522
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.
    Hollingshead LM; Faulds D; Fitton A
    Drugs; 1992 Nov; 44(5):835-57. PubMed ID: 1280569
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Calcium antagonists. Pharmacokinetic properties.
    Kates RE
    Drugs; 1983 Feb; 25(2):113-24. PubMed ID: 6339196
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Plasma protein binding of bepridil.
    Pritchard JF; McKown LA; Dvorchik BH; O'Neill PJ
    J Clin Pharmacol; 1985; 25(5):347-53. PubMed ID: 3875635
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pharmacokinetics of intravenous bepridil in patients with coronary disease.
    Lesko LJ; Benotti JR; Alpert JS; Brady PM; McCue JE; Weiner BH; Ockene IS
    J Pharm Sci; 1986 Oct; 75(10):952-4. PubMed ID: 3491897
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pharmacokinetics and metabolism of bepridil.
    Benet LZ
    Am J Cardiol; 1985 Mar; 55(7):8C-13C. PubMed ID: 3872057
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Clinical pharmacology of calcium inhibitors].
    Singlas E; Martre H; Taburet AM
    Arch Mal Coeur Vaiss; 1985 Nov; 78 Spec No():15-22. PubMed ID: 3937500
    [TBL] [Abstract][Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.